ArticleJournal of diabetes research2023
Factors Affecting Intensive Aflibercept Treatment Response in Diabetic Macular Edema: A Real-World Study.
Article in Journal of diabetes research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema.Translational vision science & technology · 2026Article
- Real-world outcomes of anti-VEGF and corticosteroid therapies for diabetic macular edema: up to 10 years of follow-up in Korean patients.Japanese journal of ophthalmology · 2026Article
- Choroidal Vascular Remodeling and Retinal Response After Aflibercept Loading in Diabetic Macular Edema.Ophthalmology science · 2026Article
- Systemic and Ocular Predictive Factors in the Treatment of Diabetic Macular Edema with Bevacizumab.Medicina (Kaunas, Lithuania) · 2026Article
- Prospective evaluation of soluble CD14 as a biomarker following five aflibercept treatments in diabetic macular edema.Scientific reports · 2025Article
- Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema.International journal of ophthalmology · 2025Article
- Wide-Field Optical Coherence Tomography in Patients with Diabetic Macular Edema.Journal of clinical medicine · 2024Article
- Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach.International journal of molecular sciences · 2024Article
- Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the systemic and ocular factors that affect the response to intensive aflibercept treatment in diabetic macular edema (DME) in a real-world setting. Methods: This retrospective cohort study evaluated 30 eyes of 23 patients with DME who underwent intensive intravitreal aflibercept injections (five monthly loading doses). Treatment response was assessed by central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at each monthly visit. The patients were categorized as good (<300 Results: The mean CRT and BCVA significantly improved after five loading injections (486.87 ± 95.46 to 334.90 ± 69.47 Conclusions: Five monthly loading doses of intravitreal aflibercept injection provided significant anatomical and visual improvements in patients with DME. Patients with longer DM duration, lower eGFR, higher serum creatinine or potassium levels, or ERM were predisposed to a suboptimal treatment response. Individual response to intensive aflibercept treatment for DME can be predicted by these systemic and ocular risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.